Evidence map›Paper›PMID 42737428›Full record

ArticleInternational journal of molecular sciences2026

Whole-Exome Sequencing Identifies Candidate Genomic Features Associated with Response to Platinum-Based Chemotherapy and Ixabepilone-Based Treatment in Ovarian Cancer.

Tobias M P Hartwich, Stefania Bellone, Orazio De Tommasi, Sarah Ottum, Victoria Ettorre, Michelle Greenman, Namrata Sethi, Cem Demirkiran, Kevin Y Yang, Ammal Abbasi and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Tobias M P HartwichDepartment of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, USA.ORCID 0000-0002-2854-2894
Stefania BelloneDepartment of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, USA.ORCID 0000-0001-5909-5292
Orazio De TommasiClinic of Gynecology and Obstetrics, Department of Women and Children's Health, University of Padua, 35100 Padua, Italy.
Sarah OttumDepartment of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, USA.ORCID 0000-0002-8729-1095
Victoria EttorreDepartment of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, USA.ORCID 0000-0002-2439-2534
Michelle GreenmanDepartment of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, USA.
Namrata SethiDepartment of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, USA.ORCID 0000-0003-1586-3338
Cem DemirkiranDepartment of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, USA.ORCID 0000-0002-7073-2819
Kevin Y YangDepartment of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, USA.ORCID 0009-0008-0167-7247
Ammal AbbasiDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA 92093, USA.
Ludmil B AlexandrovDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA 92093, USA.
Alessandro D SantinDepartment of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, USA.ORCID 0000-0003-4724-9738

Funding

High Performance Computing Instrumentation for the Yale Center for Genome AnalysisS10OD030363 · OD · YALE UNIVERSITY · PI MANE, SHRIKANT M · 2022 to 2022
$1.2M
NIH HHS S10 OD030363R-PHARM (USA)
6 · The paper itself

Abstract

Carboplatin/paclitaxel (CP) chemotherapy is the cornerstone of therapy for advanced stage ovarian cancer (OC). However, despite initial sensitivity, this regimen cannot avoid the emergence of resistance. Ixabepilone ± bevacizumab (IB) is a combination recently added to NCCN guidelines for the treatment of platinum-resistant OC. It would be desirable to identify biomarkers able to differentiate patients who are resistant to CP and IB, and biomarkers that identify which patients may benefit from IB treatment. We analyzed whole-exome-sequencing (WES) data from 49 OC patients exposed to CP, including 28 platinum-sensitive vs. 21 platinum-resistant, and 31 additional platinum-resistant patients, including 16 responders (i.e., CR/PR) vs. 15 non-responders (SD/PD) to ixabepilone ± bevacizumab. Comprehensive genetic analyses were performed to identify alterations correlated with resistance to CP and IB. WES analysis of CP responders vs. non-responders revealed differences in HRD-signatures (

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsEpothilonesExome SequencingOvarian NeoplasmsAgedBevacizumabBiomarkers, TumorCarboplatinDrug Resistance, NeoplasmFemaleHumansMiddle AgedPaclitaxelPlatinumBevacizumabBiomarkers, TumorCarboplatinEpothilonesixabepilonePaclitaxelPlatinumchemo-resistancechemo-responsenext-generation sequencingovarian cancerwhole exome sequencing

Identifiers

PMID42737428
PMCPMC13565503

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.